AL
IMPV

Aspiriant LLC’s Imperva, Inc. IMPV Stock Holding History

Aspiriant LLC’s Portfolio IMPV Stock Details IMPV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-17,500
Closed -$503K – 102
2014
Q3 		$503K Hold
17,500
– – 0.07% 57
2014
Q2 		$458K Hold
17,500
– – 0.06% 65
2014
Q1 		$975K Hold
17,500
– – 0.14% 52
2013
Q4 		$842K Buy
+17,500
New +$736K 0.13% 45

Other funds holding IMPV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRCM
Whale Rock Capital Management Boston, Massachusetts $7.74B AUM 180.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
ACM
Andor Capital Management Rye Brook, New York $232M AUM 22.72% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Aspiriant LLC's IMPV Position: Q4 2014 in Review

Aspiriant LLC sold out of Imperva, Inc. (IMPV) in Q4 2014, closing a stake of 17,500 shares — an estimated $503K sold.

Aspiriant LLC first reported a position in IMPV in Q4 2013 and held it in 4 quarters. The position peaked at $975K in Q1 2014. 137 funds tracked by Wall St. Rank hold IMPV as of Q4 2014.

  • Aspiriant LLC reported no remaining Imperva, Inc. position as of Q4 2014 after selling out during the quarter.
  • Aspiriant LLC sold 17,500 Imperva, Inc. shares in Q4 2014, an estimated $503K.
  • Aspiriant LLC first reported a position in Imperva, Inc. in Q4 2013 and held it in 4 quarters.
  • Aspiriant LLC's Imperva, Inc. position peaked at $975K in Q1 2014.
  • 137 funds tracked by Wall St. Rank held Imperva, Inc. as of Q4 2014.

Based on Aspiriant LLC's 13F filing for Q4 2014, filed 13 Feb 2015.